On Sunday, The Guru Gobind Singh Indraprastha University (GGSIPU) mentioned in a statement that they will direct a project to build up a test of low cost for fast detection of COVID-19 antibodies.
The statement further added that Dr. Gaurav Pandey, University School of Biotechnology (USBT) has submitted a translational project of Rs 98 lakh to BIRAC-DBT. It has been decided for funding in light of an examination consortium approached COVID – 19.
They mentioned that it is a proud moment for IP University to direct a multi-institutional project. The project to build up technology for the fast detection of the antibodies of COVID-19 with less infrastructural provision.
The statement said that a public sector enterprise, the Biotechnology Industry Research Council (BIRAC) arrange by the Department of Biotechnology (DBT) through its COVID -19 analysis consortium after serious assessment, will subsidize IP University and its accomplices to build up a minimal effort totally indigenous test for SARS COV2 counteracting agent testing, which can be utilized for huge scope screening of pandemic populace.
Moreover, the statement further mentioned that nowadays, the maximum of these COVID-19 tests is either a complete test or with some fundamental segments like antigens rely on substances.
Prateek Mittal from Medsource Ozone, Dr. Gaurav Pandey from IP University, and Dr. Anurag Rathore from Indian Institute of Technology (IIT), Delhi build a translational team which will build up an adaptable procedure to create the necessary antigens segments and production the purpose of care parallel stream immunoassay (LFIA) gadget.
The statement said that the LFIA test hardly requires any resource to test and give results in 15-20 minutes maximum.
The statement further added that there is no need for high-end devices and it can be easily used in remote areas. The alliance with an industrial spouse Medsource Ozone Pvt. Ltd will assure the rapid distribution of manufacturing, commercialization, and technology.